Cancer cell-specific mitochondrial reactive oxygen species promote non-heme iron uptake and enhance the proliferation of gastric epithelial cancer cell

Hiromu Ito,1 Hiromi Kurokawa,1 Aki Hirayama,2 Hiroko P. Indo,3 Hideyuki J. Majima3 and Hirofumi Matsui1,4,*

1Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan
2Center for Integrative Medicine, Tsukuba University of Technology, 4-12-7 Kasuga, Tsukuba 305-8521, Japan
3Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan
4Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto 602-8566, Japan

(Received 14 January, 2017; Accepted 12 June, 2017; Published online 26 September, 2017)

Iron is an essential nutrient for life and is involved in many important processes such as oxygen transport and DNA synthesis. However, excess amounts of iron can cause carcinogenesis by producing reactive oxygen species. Thus, the cellular transport of iron must be tightly regulated. In the human body, iron may be present as heme or non-heme iron. The mechanisms governing the cellular transport of these forms have not been clearly elucidated. We previously reported that the expression of an important heme transporter, heme carrier protein 1 was regulated by cancer-specific reactive oxygen species derived from mitochondria. In this study, we have asked if mitochondrial reactive oxygen species may also be related with non-heme iron transport. In order to address this question, we have investigated the relationship between mitochondrial reactive oxygen species and accumulation of cellular non-heme iron in a rat gastric normal, cancer and manganese superoxide dismutase-overexpressing cancer cell line, in which reactive oxygen species from mitochondria are specifically scavenged. We have also analyzed the expression of divalent metal transporter 1 and ferroportin, involved in the incorporation and excretion of non-heme iron, respectively, as well as a hypoxia-related transcription factor HIF-1α, to elucidate the molecular mechanism of non-heme iron accumulation.

Key Words: non-heme iron, mitROS, gastric epithelial cell, divalent metal transporter 1, ferroportin

For most living organisms, including humans, iron is an essential element known to participate in important processes such as transport of oxygen, DNA synthesis, and cell growth and division. Iron deficiency is associated with diseases like anemia in humans, whereas excess iron is associated with neurodegenerative disease and vascular injury, emphasizing the importance of iron homeostasis.

In recent years, excessive accumulation of iron in tissues has been correlated with carcinogenesis possibly mediated by the Fenton reaction. The Fenton reaction is an iron-specific chemical reaction in which iron (in the form of ferrous ions) reacts with hydrogen peroxide and produces hydroxyl radicals, a highly reactive form of oxygen known to cause cellular damage. Reactive oxygen species (ROS), including hydroxyl radicals, cause lipid peroxidation, oxidation of proteins, and DNA injury, ultimately lead to pathology and carcinogenesis. In support of the above association between iron accumulation and carcinogenesis, iron stored in the liver in the form of ferritin shows a marked association with hepatocellular carcinoma. Despite this, however, there is a dearth of information regarding the cellular transport of iron.

There are two forms of iron in the human body, namely, heme and non-heme iron. Heme is composed of a porphyrin ring that chelates iron, whereas non-heme iron lacks a porphyrin ring. Recently, it has been demonstrated that heme iron is transported by heme carrier protein 1 (HCP1), coded by SLC46A1, and is highly expressed in the duodenum. On the other hand, non-heme iron is transported by divalent metal transporter 1 (DMT1) and is exported to the blood stream by ferroportin (FPN), coded by SLC40A1. FPN levels are regulated by a peptide, hepcidin, that binds to FPN when intracellular and circulating iron levels are high, leading to its degradation.

Mitochondria aerobically generate ATP, the primary energy source for the cell, but are also the main source of ROS. In cancer cells, the electron transport chain is often disrupted because of mitochondrial dysfunction. Consequently, in these cells, electrons leak and react with oxygen, increasing superoxide-anion generation. This in turn results in higher ROS levels in cancer cells than in normal cells. Elevated ROS levels trigger a variety of signal transduction pathways and induce the expression and activation of several genes and proteins. Therefore, it is possible to envisage that intracellular ROS, especially mitochondrial ROS (mitROS), modulate the transport of both heme and non-heme iron in cancer cells.

We previously reported that the expression of the HCP1 heme iron transporter was enhanced in cancer cells and was controlled by mitROS. However, the detailed mechanism of non-heme iron transport and its association with mitROS are as yet uninvestigated. In this study, we have elucidated a relationship between non-heme iron transport and mitROS by studying the influence of non-heme iron incorporated by a normal rat gastric mucosal cell line, its cancer-like derivative, and its cancer-like derivative overexpressing manganese superoxide dismutase (MnSOD), a superoxide-scavenging enzyme that expresses in the mitochondrion specifically, facilitating the study of the effect of mitochondrion-derived ROS.

Materials and Methods

Cell lines. We established and used four types of gastric mucosal cell lines: a normal rat cell line, RGM1, its cancer-like
mutated cell line, RGK1, a MnSOD-overexpressing RGK cell line, RGK MnSOD, and the RGK cell line transfected with a plasmid without the MnSOD cDNA (vector alone), RGK vector. 

As mentioned above, MnSOD expresses in mitochondria and can scavenge ROS from mitochondria specifically. The protein expression levels were quantified using ImageJ (β-FeSO₄) the cells was measured in a gamma counter (AccuFLEX (Tokyo, Japan)). As a loading control, the cells was washed with PBS thrice and was immersed in Lumina forte (HRP)-linked anti-rabbit IgG antibody (#7074) (Cell Signaling Technology Japan, K.K.) antibody in Can Get Signal Immunoreaction Enhancer Solution 1 (TOYOBO (Osaka, Japan)). Cells were seeded in a 12-well cell culture plate at a density of 1 × 10⁵ cells/well and incubated overnight. After removing medium, the cells were incubated in the iron incubation buffer [25 mM Tris, 25 mM 4-morpholineethanesulfonic acid (MES), 140 mM NaCl, 5.4 mM KCl, 5 mM glucose, 1.8 mM CaCl₂, 0.4 mM sodium ascorbate, pH 6.0] containing 0.3 μM ⁵⁶FeSO₄ and 3 μM FeCl₃ for 10, 30 and 60 min at 37°C. The reduction of ⁵⁶Fe(III) to ⁵⁶Fe(II) was achieved by ⁵⁶FeSO₄ in the incubation buffer. 

The radioactive iron uptake was terminated by washing the cells with PBS thrice. Cells were detached by trypsin-EDTA treatment, and the amount of radioactive iron in the cells was measured in a gamma counter (AccuFLEX #7000, Hitachi Aloka Medical, Ltd., Tokyo, Japan).

Western blot analysis. Western blot analysis of DMT1, FPN, and hypoxia inducible factor 1 alpha subunit (HIF-1α) was performed as previously reported. Cell lysates from each cell line were prepared using NuPAGE LDS Sample buffer (Life Technologies Co.) and heated to 70°C for 15 min. Lysates (10 μl each) were applied to each well of NuPAGE NoveX 12% Bis-Tris gels (Life Technologies Co.) for SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The gel was electrophoresed at 100 V for 1.5 h, and the electrophoresed proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore Co., Billerica, MA) by applying a current of 1.2 mA/cm² for 1 h. The membrane was then immersed in blocking reagent (TOYOBO CO., LTD., Osaka, Japan) for 1 h, and was washed thrice with PBS-T (Phosphate buffered saline with 0.1% Tween 20). Blocked membrane was then incubated with anti-DMT1 (ab140977), anti-SLC40A1 (ab78066) (Abcam plc., Cambridge, UK) or anti-HIF-1α (#14179) (Cell Signaling Technology Japan, K.K.) antibody in Can Get Signal Immunoreaction Enhancer Solution 1 (TOYOBO CO., LTD., Osaka, Japan) (1:1,000) overnight. The membrane was then washed with PBS-T thrice, and then incubated with horseradish peroxidase (HRP)-linked anti-rabbit IgG antibody (#7074) (Cell Signaling Technology Japan, K.K) in Can Get Signal Immunoreaction Enhancer Solution 2 (TOYOBO) (1:1,000) for 2 h. The membrane was washed with PBS-T thrice and was immersed in Lumina forte western HRP substrate (Millipore Co.). Luminescence from the membrane was observed by LAS4000 (GE Health Care Japan, Tokyo, Japan). As a loading control, β-actin was detected with β-actin antibody (#4967) (Cell Signaling Technology Japan, K.K.). The protein expression levels were quantified using ImageJ software (National Institutes of Health, Bethesda, MA).

Measurement of ROS generation by electron spin resonance. Intracellular ROS generation after iron treatment was detected by electron spin resonance (ESR) according to a previous study. Briefly, cells were seeded on a sterilized glass cover slide (49 × 5 × 0.2 mm) at confluency and incubated overnight. Cells were then exposed to fresh medium containing 500 μM FeSO₄ for 1 h and then immersed in the respiratory buffer containing 5 mM succinate (Sigma-Aldrich Japan K.K., Tokyo, Japan), 5 mM malate (Wako), 5 mM glutamate (Sigma-Aldrich Japan K.K.), 5 mM nicotinamide adenine dinucleotide (NADH) (Sigma-Aldrich Japan K.K.) and 5 μl 5,5-dimethyl-1-pyrrrole-N-oxide (DMPO) (Dojindo Laboratories, Kumamoto, Japan). The slide was set in a tissue glass, and ESR spectra were obtained using a JEOL-TE X-band spectrometer (JEOL, Ltd., Tokyo, Japan) using the following measurement conditions: 10 mW incident microwave power, 9.4 GHz frequency, and 0.1 mT field modulation amplitude. The experiments were performed three times independently.

Cell proliferation assay. The effect of iron on cellular proliferation was investigated using the Cell Counting Kit 8 (Dojindo Laboratories), a water-soluble tetrazolium (WST)-8 based colorimetric assay. Cells were seeded in a 96-well cell culture plate at a density of 1 × 10⁵ cells/well and incubated overnight. They were then incubated in 100 μl iron incubation buffer containing 0, 1, 2, 5, 10, 20, 50 or 100 μM FeSO₄ for 6 h at 37°C. After incubation, cells were washed twice with PBS and the medium was replaced with fresh medium containing 10% Cell Counting Kit 8 reagent and further incubated. The absorbance at 450 nm was measured using a DTX880 multi-mode micro-plate reader (Beckman Coulter Inc., Brea, CA).

Statistical analysis. Statistical analysis was performed using SPSS statistics 21 software (IBM Corporation, NY). Tukey’s test or Games-Howell’s test was used for comparison of more than two data sets and Student’s t test for comparison of two data sets; p<0.01 and p<0.05 were considered statistically significant.

Results

Specific accumulation of non-heme iron in cancer cells. We compared the incorporation of non-heme iron among normal cells (RGM1), cancer cells (RGK1), and MnSOD-overexpressing (RGK MnSOD) and vector-control (RGK vector) cancer cells by measuring the amount of radioactive iron present in lysates made from each cell line cultured in the presence of ⁵⁶Fe. RGK1 and RGK vector-control cells showed a dramatic increase in the accumulation of radioactive iron in a time-dependent manner, whereas RGM1 and RGK MnSOD cells did so only marginally (Fig. 1). Cancer cells showed significantly greater accumulation of radioactive iron than normal cells did, particularly at 60 min. Importantly, MnSOD-overexpression attenuated iron uptake, indicating that intracellular mitROS were indeed associated with cellular uptake of non-heme iron.

Expression of iron transport proteins and hypoxia transcription factor in cells. Next, we compared the expression levels of the DMT1 and FPN iron transports in the above cells by western blot analysis. DMT1, involved in iron uptake, was expressed to a higher level in cancer cells than in normal and MnSOD-overexpressing cancer cells (Fig. 2a). In contrast, the iron excretion protein FPN showed lower expression in cancer cells than in normal and MnSOD-overexpressing cells (Fig. 2b). These data suggest a tendency of cancer cells to retain and actively take up iron, in contrast to normal cells, and are in agreement with the greater uptake of extracellular iron by cancer cells (Fig. 1). Additionally, the expression of HIF-1α was also higher in RGK1 cells and decreased in RGK MnSOD cells (Fig. 2c) in line with DMT1 expression levels in these cells.

Iron exposure-induced ROS generation in cancer cells. Given the increased iron levels in cancer cells, we measured intracellular ROS levels using ESR in cells treated with 500 μM FeSO₄. Fig. 3a showed ROS levels were significantly higher in RGK1 and vector cells after treatment of iron, whereas ESR peaks were slightly detectable in RGM1 cells. In RGK MnSOD cells, weak peaks were observed without iron treatment and signal increase was observed after FeSO₄ treatment. In all of cell lines, relative signal intensities were increased by iron treatment, however, the increase level was suppressed by overexpression of ¹⁰⁶Fe(II) and ¹⁰⁸Fe(II) was achieved by ¹⁰⁶FeSO₄ in the incubation buffer. 

Iron exposure-induced ROS generation in cancer cells.
MnSOD in cancer cells. In addition, the increase of peak intensity in normal cells was lower than other cancer cell lines (Fig. 3b). These results indicated that iron treatment induced cancer cellspecific enhancement in ROS generation and that the ROS were primarily derived from mitochondria because MnSOD expresses in mitochondria specifically and overexpression of MnSOD suppressed the increase of ROS generation in cancer cells.

**Enhancement of cancer cellular proliferation.** We next attempted to determine whether the incorporation of iron had any influence on cellular proliferation. In normal (RGM1) cells, cellular proliferation was not induced, even at FeSO₄ concentrations of up to 50 μM, and at 100 μM, the cell viability was lost. However, in all the other cell lines, proliferation increased with extracellular iron in a dose-dependent manner and, unlike in RGM1 cells, loss of viability was not observed even at 100 μM iron exposure. In particular, RGK1 cells proliferated dramatically upon iron treatment and their proliferation was significantly greater than that of normal cells at iron concentrations greater than 20 μM. Further, MnSOD overproduction suppressed proliferation potential to some extent, indicating that exposure to non-heme iron may promote cancer cell-specific proliferation.

**Discussion**

We have previously reported that cancer cells produce larger amounts of ROS than normal cells do, and MnSOD expression in cancer cells suppresses ROS production. Since MnSOD is specifically able to scavenge ROS derived from mitochondria, using MnSOD overexpressing cancer cells (RGK MnSOD) allows direct examination of the influence of mitROS on iron uptake and cell proliferation in cancer cells. Our study demonstrates the importance of mitROS in the regulation of cancer cell-specific iron uptake. Additionally, in this study, we have demonstrated for the first time that mitROS play an important role in the incorporation of non-heme iron in gastric epithelial cells.
Our study establishes an important molecular link between iron uptake and mitROS in cancer cells. As seen in Fig. 1, RGK1 and RGK vector cells accumulate radioactive iron in a time-dependent manner, whereas RGK MnSOD cells do so to a much lower extent. RGM1 cells also showed much lower iron accumulation compared to RGK1 cells. Additionally, the expression level of DMT1 in RGK1 was higher than that in RGK MnSOD and RGM1 cells, whereas FPN expression was higher in RGK MnSOD cells than in RGK1 cells (Fig. 2). These data indicate that mitROS influence the expression level of the non-heme iron incorporation protein DMT1 and its excretion protein FPN, and that these proteins in turn regulate the levels of intracellular iron. Thus, although RGK1 cancer cells are poised to incorporate and accumulate non-heme iron, RGM1 normal cells and RGK MnSOD cells are unable to incorporate large amounts of non-heme iron and indeed may readily allow its excretion.

The expression of iron uptake proteins has been reported to be related to hypoxia. In hypoxic environments, HIF, which is a transcription factor, is stabilized and activates the transcription of various genes involved in iron metabolism such as erythropoietin and heme oxygenase-1. There are several types in HIFs reported, such as HIF-1α and HIF-2α, which are subunits of the HIF-1 and HIF-2 complexes, and they induce transcription by interacting with hypoxia response elements. Qian et al. reported that HIF-1 stabilization alone is not adequate to induce iron incorporation via DMT1 upregulation. On the other hand, Mastrogiannaki et al. reported that HIF-2α, but not HIF-1α, regulated the expression of DMT1. The activation of HIFs is known to be linked to ROS, and mitROS in particular seem to play an important role in this process. Therefore, we propose that stabilization of HIFs by mitROS may regulate the expression of DMT1, and promote cellular uptake of non-heme iron. This hypothesis is supported by the observation that scavenging cancer cell-specific mitROS led to suppression of DMT1 expression. Indeed, HIF-1α levels in RGK1 cells were also much higher than in MnSOD overexpressing cells (Fig. 2c). Additionally, mitROS also appear to inhibit the expression of FPN. Hepcidin, a peptide hormone, is known to bind to FPN, causing the latter to be degraded. Hepcidin is induced not only in response to increased levels of intracellular iron but also by the action of proinflammatory cytokines such as interleukin-6 (IL-6). Besides, although hepcidin is produced mainly in the liver, it is upregulated in gastric parietal cells by IL-6 or infection of Helicobacter pylori, and mitROS is already implicated in this process. Thus, enhancement of hepcidin production due to mitROS may explain the suppression of FPN expression in cancer cells, allowing reduced iron efflux. Alternatively, hepcidin-independent regulation of FPN levels may be mediated by HIF-2α as demonstrated by Taylor et al.

Our results demonstrate that iron accelerated mitROS production and proliferation in cancer cells but not in normal cells (Fig. 3 and 4). Excess iron is known to damage mitochondrial DNA and cause respiratory dysfunction in normal cells, and intracellular iron is associated with cancer cell proliferation.
decrease of iron levels by phlebotomy can reduce the risk of hepatocellular carcinogenesis in patients with chronic hepatitis C.\textsuperscript{14} Further, Chen et al.\textsuperscript{15} have reported that lower expression of FPN enhances cellular proliferation and causes poor prognosis in breast cancer. It appears then, that an overload of iron is likely to enhance the “cancerous” characteristics of cancer cells by enhancing their proliferative potential. Since MnSOD overexpression attenuates ROS production and proliferation of cancer cells in response to exposure to iron, we suggest that the signaling pathway triggered by mitROS may reinforce the proliferative properties of cancer cells.

In conclusion, we have shown that cancer cells incorporate larger amounts of non-heme iron than normal cells do and that this phenomenon may be attributed to the enhancement of expression of iron transport protein DMT1 by mitROS. Intracellular overload of iron in turn may induce cancer cells to produce excess ROS and hence promote cancer-cell specific proliferation. These results may be associated with ROS-related disease and bring some adverse effects to patients with disease such as inflammation and cancer.

Acknowledgments

This study was partially supported by JSPS Grant-in-Aid for Scientific Research (KAKENHI) #15K15188 and #23106005.

Conflict of Interest

No potential conflicts of interest were disclosed.

References

1. Bagg A, Neilands JB. Ferric uptake regulation protein acts as a repressor, employing iron (II) as a cofactor to bind the operator of an iron transport operon in Escherichia coli. Biochim 1987; 26: 5471–5477.

2. Zhang C. Essential functions of iron-requiring proteins in DNA replication, repair and cell cycle control. Protein Cell 2014; 5: 750–760.

3. Yu Y, Kovacevic Z, Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle 2007; 6: 1982–1994.

4. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004; 5: 863–873.

5. Balla J, Vercellotti GM, Jeney V, et al. Identification of an intestinal heme transporter. FEBS Lett 2001; 510: 87–91.

6. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Cancer Metastasis Rev 2006; 25: 695–705.

7. Ito H, Matsui H, Tamura M, Majima HJ, Indo HP, Hyodo I. Mitochondrial reactive oxygen species accelerate the expression of heme carrier protein 1 and enhance photodynamic cancer therapy effect. J Clin Biochem Nutr 2014; 55: 67–71.

8. Schumacker PT. Reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism. Cancer Res 2009; 69: 2357–2383.

9. Wu WS. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 2006; 25: 695–705.

10. Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J Biol Chem 2005; 530: 39485–39492.

11. Indo HP, Davidson M, Yen HC, et al. Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion 2007; 7: 106–118.

12. Shimokawa O, Matsui H, Nagano Y, et al. Neoplastic transformation and induction of H2O2 by adenine triphosphate by N-nitro-L-arginine. In Vitro Cell Dev Biol Anim 2008; 44: 26–30.

13. Indo HP, Inanami O, Kounuma T, et al. Roles of mitochondria-generated reactive oxygen species on X-ray-induced apoptosis in a human hepatocellular carcinoma cell line, HLE. Free Radic Res 2012; 46: 1029–1043.

14. Priwitzerova M, Nie G, Sheftel AD, Pospisilova D, Divoky V, Ponka P. Functional consequences of the human DMT1 (SLC11A2) mutation on protein expression and iron uptake. Blood 2005; 106: 3985–3987.

15. Pelicano H, Lu W, Zhou Y, et al. Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism. Cancer Res 2009; 69: 2357–2383.

16. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004; 5: 863–873.

17. Balla J, Vercellotti GM, Jeney V, et al. Identification of an intestinal heme transporter. FEBS Lett 2001; 510: 87–91.
(DMT1) in rat pheochromocytoma (PC12) cells. *Biochem Pharmacol* 2005; 69: 1647–1655.

26 Wenger RH. Cellulose adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. *FASEB J* 2002; 16: 1151–1162.

27 Yang ZZ, Zou AP. Transcriptional regulation of heme oxygenases by HIF-1α in renal medullary interstitial cells. *Am J Physiol Renal Physiol* 2001; 281: F900–F908.

28 Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. *Nat Med* 2003; 9: 677–684.

29 Qian ZM, Wu XM, Fan M, et al. Divalent metal transporter 1 is a hypoxia-inducible gene. *J Cell Physiol* 2011; 226: 1596–1603.

30 Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaux C. HIF-2α, but not HIF-1α, promotes iron absorption in mice. *J Clin Invest* 2009; 119: 1159–1166.

31 Jung SN, Yang WK, Kim J, et al. Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells. *Carcinogenesis* 2008; 29: 713–721.

32 Emerling BM, Platanias LC, Black E, Nebreda AR, Davis RJ, Chandel NS. Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. *Mol Cell Biol* 2005; 25: 4853–4862.

33 Qi Y, Tian X, Liu J, et al. Bnip3 and AIF cooperate to induce apoptosis and cavitation during epithelial morphogenesis. *J Cell Biol* 2012; 198: 103–114.

34 Chandel NS, McClintock DS, Feliciano CE, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1α during hypoxia: a mechanism of O2 sensing. *J Biol Chem* 2000; 275: 25130–25138.

35 Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science* 2004; 306: 2090–2093.

36 Torti SV, Torti FM. Ironing out cancer. *Cancer Res* 2011; 71: 1511–1514.

37 Schwarz P, Kübler JA, Strnad P, et al. Hepcidin is localised in gastric parietal cells, regulates acid secretion and is induced by *Helicobacter pylori* infection. *Gut* 2012; 61: 193–201.

38 Bulua AC, Simon A, Maddipati R, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). *J Exp Med* 2011; 208: 519–533.

39 Kim JM, Kim JS, Lee JY, et al. Vacuolating cytotoxin in *Helicobacter pylori* water-soluble proteins upregulates chemokine expression in human eosinophils via Ca2+ influx, mitochondrial reactive oxygen intermediates, and NF-κB activation. *Infect Immun* 2007; 75: 3373–3381.

40 Taylor M, Qu A, Anderson ER, et al. Hypoxia-inducible factor-2α mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. *Gastroenterology* 2011; 140: 2044–2055.

41 Harley A, Cooper JM, Schapira AH. Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson’s disease. *Brain Res* 1993; 627: 349–353.

42 Gao X, Campian JL, Qian M, Sun XF, Eaton JW. Mitochondrial DNA damage in iron overload. *J Biol Chem* 2009; 284: 4767–4775.

43 Nirei K, Matsuoka S, Nakamura H, Matsumura H, Moriyama M. Incidence of hepatocellular carcinoma reduced by phlebotomy treatment in patients with chronic hepatitis C. *Intern Med* 2015; 54: 107–117.

44 Chen Y, Zhang S, Wang X, et al. Disordered signaling governing ferroportin transcription favors breast cancer growth. *Cell Signal* 2015; 27: 168–176.